Press Releases

Release year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Release Tag:

December 23, 2013
Genetic Technologies Announces Issue of Redeemable Convertible Note and Receipt of Funds

December 18, 2013
Genetic Technologies Announces Share Reduction Schedule With Major Shareholder

December 06, 2013
Genetic Technologies Announces Publication Highlighting Cost-Effectiveness of BREVAGen(TM) in Cancer Prevention Research

October 31, 2013
Genetic Technologies Announces Financial Results for First Fiscal Quarter Ended September 30, 2013

October 15, 2013
Genetic Technologies Announces Temporary Corporate Restructure

October 01, 2013
Genetic Technologies Announces Record Quarter for BREVAGen(TM)

September 26, 2013
ImmunAid Limited Commences Second Round Fundraising Program

September 23, 2013
Achaogen Announces Agreement With FDA on a Special Protocol Assessment for a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

September 09, 2013
Aquilo Capital Management Submits Open Letter to the Board of Directors and Fellow Shareholders of Astex Pharmaceuticals

August 30, 2013
Genetic Technologies Receives Certification for New York State

August 20, 2013
Alchemia Reports Record Fondaparinux Quarterly Profit Share

August 05, 2013
Vital Therapies, Inc. Receives Orphan Designation in Europe

August 01, 2013
Genetic Technologies Announces Financing and Intended Use of Proceeds

July 10, 2013
Genetic Technologies Announces U.S. Patent Office Allows First Patent for ImmunAid

July 01, 2013
Genetic Technologies Announces Record Number of BREVAGen(TM) Tests

June 24, 2013
Genetic Technologies Settles Its Dispute With Ingelheim, Germany-Based Bioscientia Institute for Medical Diagnostics

June 24, 2013
Genetic Technologies Announces Independent Clinical Validation Study in Support of the Utilization of BREVAGen(TM)

June 19, 2013
Genetic Technologies Executes Agreement With Further Nationwide Provider Network for BREVAGen(TM)

June 17, 2013
Genetic Technologies Provides U.S. Gene Patenting Update

May 22, 2013
Alchemia Limited Provides Company Update

May 20, 2013
Genetic Technologies Executes Agreement With MultiPlan, Inc., a Nationwide Provider Network

May 16, 2013
Vital Therapies, Inc. Adds Two New Board Members

May 09, 2013
Sunshine Heart, Inc. Announces First Patient Implanted in C-Pulse System European Post-Market Study

May 03, 2013
Genetic Technologies Executes Agreement With Nationwide Provider Network

April 30, 2013
Genetic Technologies Announces Financial Results for Quarter Ended March 31, 2013

April 23, 2013
Alchemia Announces Multi-Target Drug Discovery Collaboration With AstraZeneca on VAST Discovery Platform

April 16, 2013
Sunshine Heart, Inc. Closes Public Offering of Common Shares

April 11, 2013
Sunshine Heart, Inc. Prices $13.1 Million Public Offering of Common Shares

April 10, 2013
Sunshine Heart, Inc. Announces Proposed Public Offering of Common Shares

April 04, 2013
Vital Therapies, Inc. Enrolls First Patient in VTI-208, a Controlled, Randomized Phase 3 Trial Evaluating the ELAD(R) System in Alcohol-Induced Liver Decompensation

April 04, 2013
IDT Ltd Appoints Dr. Paul MacLeman CEO

March 25, 2013
Vital Therapies, Inc. Announces Increase in Financing

March 22, 2013
Alchemia Announces Addition of Two Board Members

March 15, 2013
Genetic Technologies Provides U.S. Patent Re-Examination Update

March 13, 2013
Sunshine Heart Appoints Jon Salveson to Board of Directors

March 11, 2013
Sunshine Heart Reports Fourth Quarter and Full Year 2012 Results

March 06, 2013
Alchemia Granted Key US Patent

March 06, 2013
SymBio Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

February 28, 2013
Alchemia Completes Enrolment in Pivotal Phase III HA-Irinotecan Trial of Metastatic Colorectal Cancer

February 26, 2013
Sunshine Heart to Attend Upcoming Investor Conferences

February 22, 2013
Genetic Technologies Announces Financial Results for Half-Year Ended 31 December 2012

February 18, 2013
Alchemia Achieves $3.4 Million Quarterly Fondaparinux Profit Share

February 18, 2013
Alchemia Appoints Charles Walker as Chief Executive Officer

February 12, 2013
Biota Pharmaceuticals Reports Second Quarter Financial Results and Corporate Update

January 30, 2013
Sunshine Heart Appoints Warren Watson to Board of Directors

January 29, 2013
Sunshine Heart to Delist From the Australian Securities Exchange

January 15, 2013
Sunshine Heart Enters Into a $25 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC

January 07, 2013
Sunshine Heart Provides Clinical Update